# BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation

> **NCT05959252** · PHASE2 · RECRUITING · sponsor: **Sydney Local Health District** · enrollment: 80 (estimated)

## Conditions studied

- Extracorporeal Membrane Oxygenation Complication

## Interventions

- **DRUG:** Unfractionated heparin
- **DRUG:** Bivalirudin

## Key facts

- **NCT ID:** NCT05959252
- **Lead sponsor:** Sydney Local Health District
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05959252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05959252, "BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05959252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*